Naperville, IL -- (SBWIRE) -- 03/20/2014 -- Reportstack, provider of premium market research reports announces the addition of Molecular Diagnostics: An Insight to Rising Markets and Trends in Cancer and Prenatal Technologies market report to its offering
Molecular Diagnostics: An Insight to Rising Markets and Trends in Cancer and Prenatal Technologies covers market research, relevant disease background, and a number of rising technologies available to physicians and clinicians in the cancer and prenatal space. This report focuses on market background of the areas that are covered, including lung, breast, thyroid and blood cancers (specifically leukemia and lymphoma), as well as pre-conception genetic information and prenatal diagnostics.
Included in this Report:
- Cancer diagnostics companies interviewed include: GeneCentric, Veracyte, Adaptive Biotechnologies
- Genetic and prenatal diagnostics research companies including GenePeeks and Verinata Health
- Comprehensive coverage of survey results (n=123) from the various companies and researchers working in molecular diagnostics.
- A company directory which was created for this report. This includes several seasoned and emerging companies, their areas of focus, and the status of their technologies.
Molecular Diagnostics: An Insight to Rising Markets and Trends in Cancer and Prenatal Technologies covers market research, relevant disease background, and a number of rising technologies available to physicians and clinicians.
This report has been divided into five parts. The first part of this report will focus on market growth and molecular diagnostic interest (Chapter 2). This chapter will discuss a brief overview of the growth of molecular diagnostics in several areas of cancer as well as prenatal diagnostics. These areas will be further discussed in later sections.
Part II focuses on cancer diagnostics, covering lung, breast, thyroid and blood cancers. These sections will include background information on all four types of cancers including risk, incidence, symptoms, early detection, and even targets under investigation. Information on a variety of companies working in the related cancer spaces and exclusive interviews with CEOs, Presidents, and Founders are also included. The companies that are featured include GeneCentric, which has two platforms available for breast and lung cancer; Veracyte, which has a platform for screening thyroid nodules found indeterminate by flow cytometry; and Adaptive Biotechnologies, which has a platform specifically for monitoring minimal residual disease (MRD) in blood cancers. Although these companies focus on different cancer-types, it is interesting to see the approach they are taking to meet market needs and tackle various diseases.
Part III of the report will focus on the prenatal aspect, covering background information and the growth of prenatal diagnostics. There are a variety of growing technologies and companies in this space. As far as genetic information is concerned, GenePeeks has a platform used for creating hypothetical genomes. This technology creates a portfolio of genomic combinations for clients and potential donors, screening for a number of genetic defects that could be present in these hypothetical children. Also included in this section is information on sequence-based cell-free DNA testing and fetal cell isolation. These are two noninvasive strategies currently on the rise to alleviate the need for invasive testing (either amniocentesis or chorionic villus sampling). A company featured in this section is Verinata, which uses sequence-based cell-free DNA testing, a screening method that is currently recommended by the American College of Obstetricians and Gynecologists (ACOG).
The fourth part of this report will focus on survey results. Illustrated with several charts and graphs, this section will cover a number of techniques in development and challenges faced by the research and development community.
Finally, the fifth and final part is a complimentary company directory, featuring companies that are both mentioned and not mentioned in this report. This section gives insight to product development, clinical status, challenges, and competitive advantages.
To view the table of contents for this market research report please visit